The device supports all seven tests done for NBS globally
Mylab Discovery Solutions has introduced patent-pending Point-of-Care Device named MyNeoShield for New-born Screening (NBS). The device supports all seven tests done for NBS globally.
With Mylab’s device, results can be obtained within just 4 hours on the spot compared to traditional techniques that take up to 24 hours post sample receipt which may take additional 48-72 hours. This rapid turnaround time ensures that any potential health issues are identified and addressed promptly. Smaller healthcare facilities, including nursing homes and clinics, can now offer newborn screening without the need for expensive equipment or extensive resources.
Hasmukh Rawal, Co-founder & Managing Director of Mylab, expressed his enthusiasm for this development, saying, “At Mylab, we are deeply committed to advancing healthcare through innovation and accessibility. Our Point-of-Care Device for New-born Screening is a testament to that commitment. By making screening faster and more accessible, we aim to save lives and ensure that every child has the opportunity for a healthy and promising future.”
This device is set to be available commercially from November. The company plans to take the device to global markets with its partners.